ADVM Adverum Biotechnologies, Inc.

2.90
-0.05  -1.69%
Previous Close 2.95
Open 2.95
Price To book 0.52
Market Cap 120.98M
Shares 41,718,000
Volume 64,103
Short Ratio 1.79
Av. Daily Volume 229,221

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17541069
  2. 8-K - Current report 162044585
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161981574
  4. 8-K - Current report 161981428
  5. 8-K - Current report 161975418

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 4Q 2017.
ADVM-043
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
AVA-101
Wet age-related macular degeneration (Wet-AMD)

Latest News

  1. Adverum Biotechnologies to Present At Phacilitate Cell & Gene Therapy World 2017
  2. Is KCAP Financial Inc (KCAP) A Good Stock to Buy?
  3. Is Osiris Therapeutics, Inc. (OSIR) A Good Stock To Buy?
  4. Is Adverum Biotechnologies Inc (ADVM) a Good Stock to Buy?
  5. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement
  6. ETFs with exposure to Adverum Biotechnologies, Inc. : December 5, 2016
  7. ADVERUM BIOTECHNOLOGIES, INC. Financials
  8. Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
  9. Adverum Biotechnologies to Present at Upcoming Investor Conferences
  10. Adverum Biotechnologies to Present at Upcoming Investor Conferences
  11. Adverum Biotechnologies, Inc. Reports Third Quarter 2016 Financial Results
  12. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
  13. Adverum Biotechnologies, Inc. Reports Third Quarter 2016 Financial Results
  14. Adverum (ADVM) Q3 Earnings Preview: What's in the Cards?
  15. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  16. Adverum Biotechnologies, Inc. Announces New Executive Chair and CEO
  17. Adverum Biotechnologies Provides Update on Alpha-1 Antitrypsin Deficiency Program
  18. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
  19. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  20. Adverum Biotechnologies Presents Preclinical Data on Novel Gene Therapy Candidates for the Treatment of Wet AMD at The Retina Society 2016 Annual Meeting

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17541069
  2. 8-K - Current report 162044585
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161981574
  4. 8-K - Current report 161981428
  5. 8-K - Current report 161975418
  6. 8-K - Current report 161935954
  7. 8-K - Current report 161935103
  8. CT ORDER - Confidential treatment order 161930020
  9. 8-K - Current report 161888197
  10. 8-K - Current report 161868759